Results 211 to 220 of about 1,419,720 (263)

The Effect of Mineralocorticoid Receptor Antagonists on Heart Failure with Nonreduced Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]

CJC Open
De Luca C, Bhatt H, Gupta A, Yahyavi A, Banivaheb B, Rayner D, Anderson K, Zieroth S, Virani SA, Foroutan F, Aleksova N.   +10 more
europepmc   +1 more source

Will mineralocorticoid receptor antagonists give impact on HFpEF pharmacotherapy in addition to SGLT2 inhibitors? [PDF]

Eur Heart J Cardiovasc Pharmacother
Komiyama M, Hasegawa K, Rosano GMC.
europepmc   +1 more source

Contemporary evidence of non-steroidal mineralocorticoid receptor antagonists in cardio-kidney-metabolic syndrome. [PDF]

Future Cardiol
Attachaipanich T, Kaewboot K, Attachaipanich S.   +2 more
europepmc   +1 more source

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice. [PDF]

JACC Adv
Alfarano M, Marchionni G, Costantino J, Ballatore F, Verardo R, Miraldi F, Ciciarello FL, Petramala L, Letizia C, Frustaci A, Chimenti C.   +10 more
europepmc   +1 more source

Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia. [PDF]

Am Heart J Plus
Hassen M, Worku BT, Solomon T, Demessie MB, Wendie TF, Muhammed OS, Gobezie MY.   +6 more
europepmc   +1 more source

An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]

Eur J Heart Fail
Kobayashi M, Duarte K, Ferreira JP, Baudry G, Monzo L, McMurray JJV, Van Veldhuisen DJ, Pitt B, Zannad F, Girerd N.   +9 more
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Dibo P, Mareddy NSR, Kojima GSA, Ershed M, Obi OS, Razaq S, Kumar V.   +6 more
europepmc   +1 more source

Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Muhammad Daniyal S, Ajaz H, Riaz M, Murad Khatoon N, Aftab Z, Tauqir Gondal H, Gul I, Sarwar M, Batool F, Fahim SL, Noor A, Khalid A, Ashraf DA, Jabarkhil R.   +13 more
europepmc   +1 more source

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study. [PDF]

Lancet Reg Health Eur
Svanström H, Mkoma GF, Hviid A, Pasternak B.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mineralocorticoid receptor antagonists

2023
Abstract Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines, while recommending MRAs, do not make a clear recommendation as to which MRAs should be used, how doses should be titrated, or ...
Bertram Pitt, João Pedro Ferreira, Faiez Zannad   +2 more
openaire   +1 more source